Müller-Oerlinghausen B, Berghöfer A, Bauer M. Bipolar disorder. Lancet 2002;359:241–47.
Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436–42.
American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159 (4 suppl):1–50.
Goodwin GM. Evidence-based guidelines for treating bipolar disorder: revised second edition—recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009;23:346–88.
National Institute for Health and Clinical Excellence. Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. http://guidance.nice.org.uk/CG38
accessed Nov 19, 2009).
Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004;161:217–22.
Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behaviour and all-cause mortality in patients with mood disorders: a systematic review of randomised trials. Am J Psychiatry 2005;162:1805–19.
Soares-Weiser K, Bravo Vergel Y, Beynon S, et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol Assess 2007;11:1–226.
Fenn HH, Robinson D, Luby V, et al. Trends in pharmacotherapy of schizoaffective and bipolar affective disorders: a 5-year naturalistic study. Am J Psychiatry 1996;153:711–13.
Sanderson DR. Use of mood stabilizers by hospitalized geriatric patients with bipolar disorder. Psychiatr Serv 1998;49:1145–47.
Citrome L, Levine J, Allingham B. Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health. Psychiatr Q 1998;69:283–300.
Blanco C, Laje G, Olfson M, Marcus SC, Pincus HA. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 2002;159:1005–10.
MacRitchie K, Geddes JR, Scott J, Haslam D, de Lima M, Goodwin G. Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev 2004;4:CD004052.
Macritchie KA, Geddes JR, Scott J, Haslam DR, Goodwin GM. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2001;3:CD003196.
Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998;155:12–21.
Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. Nature 2002;417:292–95.
Geddes J, Goodwin G. Bipolar disorder: clinical uncertainty, evidence-based medicine and large-scale randomised trials. Br J Psychiatry 2001; 178:S191–94.
Zarate J, Singh J, Manji HK. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry 2006;59:1006–20.
Kemp DE, Gao K, Ganocy SJ, et al. A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and co-occurring substance abuse or dependence. J Clin Psychiatry 2009;70:113–21.
Geddes JR, Rendell JM, Goodwin GM. BALANCE: a large simple trial of maintenance treatment for bipolar disorder. World Psychiatry 2002;1: 48–51.
Rendell JM, Juszczak E, Hainsworth J, et al. Developing the BALANCE trial—the role of the pilot study and start-up phase. Bipolar Disord 2004; 6:26–31.
Lang JM. The use of a run-in to enhance compliance. Stat Med 1990; 9:87–93.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn.
American Psychiatric Association, 1994.
Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991;48:1082–88.
Jones SH, Thornicroft G, Coffey M, Dunn G. A brief mental health outcome scale—reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1995;166:654–59.
Kind P. The Euroqol instrument: an index of health related quality of life. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials, 2nd edn. Philadelphia: Lippincott-Raven Publishers, 1996:191–201.
Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. Is this patient taking the treatment as prescribed? JAMA 1993;269:2779–81.
Findling RL, McNamara NK, Youngstrom EA, et al. Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005;44: 409–17.
Calabrese JR, Shelton MD, Rapport DJ, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005;162:2152–61.
Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452–54.
Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2007;64:543–52.
Pablos MA, Barr RG, Shea S. Run-in periods in randomized trials: implications for the application of results in clinical practice. JAMA 1998; 279:222–25.
Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004;65:432–41.
Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007; 356:1711–22.
Ostacher MJ, Nierenberg AA, Iosifescu DV, et al. Correlates of subjective and objective burden among caregivers of patients with bipolar disorder. Acta Psychiatr Scand 2008;118:49–56.
Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009; 194:4–9.
Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009; 360:1597–605.